The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Growth Is Projected For The Radiopharmaceuticals Market During The Forecast Period 2026–2030?
The radiopharmaceuticals market has experienced significant growth in recent years. It is forecast to rise from $7.3 billion in 2025 to $8.25 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.0%. This expansion during the historic period is linked to factors such as the adoption of nuclear imaging technologies, an increase in cancer diagnosis rates, the availability of radioisotopes, the growth of hospital-based nuclear medicine, and regulatory approvals for diagnostic agents.
The radiopharmaceuticals market is projected to experience substantial expansion over the upcoming years. By 2030, this market is anticipated to reach a value of $13.68 billion, advancing with a compound annual growth rate (CAGR) of 13.5%. This projected increase is largely due to several factors, including the advancement of precision oncology, a heightened demand for targeted radiotherapies, the proliferation of diagnostic imaging centers, significant investments in cyclotron infrastructure, and continuous technological progress in isotope production. Key developments influencing this period encompass the growing application of radiopharmaceuticals in oncology, the expansion of theranostics applications, broader use of PET and SPECT imaging, intensified development of targeted radiotherapies, and enhancements to nuclear medicine infrastructure.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3471&type=smp
What Drivers Are Expected To Influence The Radiopharmaceuticals Market During The Forecast Period?
The growing incidence of cancer and cardiovascular diseases is anticipated to fuel the demand for the radiopharmaceuticals market. Radiopharmaceuticals are emerging as a secure and potent therapeutic alternative to conventional medicines. Thanks to benefits such as targeted therapy, radiopharmaceuticals offer radiologists a distinct advantage in treating cancer and cardiovascular diseases. Globally, cancer is recognized as the second leading cause of mortality, contributing to around 1 in 6 deaths worldwide. As an illustration, in April 2024, the International Agency for Research on Cancer (IARC), a specialized agency based in France, reported that in 2022, approximately 20 million new cancer cases and 9.7 million cancer-related deaths occurred globally. By 2040, these numbers are projected to increase to 29.9 million new cases and 15.3 million deaths annually. Consequently, the escalating number of cancer and cardiovascular disease cases is expected to boost the demand for radiopharmaceuticals in their treatment.
What Market Segments Are Evaluated Within The Radiopharmaceuticals Market?
The radiopharmaceuticals market covered in this report is segmented –
1) By Type: Diagnostic, Therapeutic
2) By Application: Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Musculoskeletal, Respiratory, Nephrology, Other Applications
3) By End User: Hospitals And Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes
Subsegments:
1) By Diagnostic: Positron Emission Tomography (PET) Radiopharmaceuticals, Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
2) By Therapeutic: Alpha Emitters, Beta Emitters, Brachytherapy
What Industry Trends Are Redefining The Radiopharmaceuticals Market?
Leading organizations within the radiopharmaceuticals market are increasingly forging strategic alliances to drive innovation and broaden the availability of advanced diagnostic and therapeutic solutions. These joint efforts concentrate on enhancing radiopharmaceutical development, strengthening regional manufacturing capabilities, and meeting the growing demand for precision imaging and targeted therapies. For example, in June 2023, the University of Pittsburgh Medical Center (UPMC), a US-based hospital system, partnered with PharmaLogic Holdings Corporation to collaboratively develop and produce new radiopharmaceuticals at a Pittsburgh facility. This collaboration seeks to expand access for patients and clinicians to cutting-edge diagnostic and therapeutic agents not currently offered in nearby areas. Through their non-exclusive agreement, UPMC and PharmaLogic will transform experimental radiopharmaceuticals into practical clinical medications, thereby supporting wider commercialization and accelerating the adoption of novel nuclear medicine treatments.
Who Are The Top Market Participants Influencing The Radiopharmaceuticals Market?
Major companies operating in the radiopharmaceuticals market are Cardinal Health, Curium Pharma, Siemens Healthineers AG, Novartis AG, General Electric Company (GE), IBA Group, Bayer AG, Lantheus Medical Imaging Inc., Bracco Imaging S.p.A., Eckert & Ziegler, Nihon Medi-Physics Co. Ltd., Fujifilm Corporation, ANSTO, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Bracco Imaging SpA., Canon Inc., China Isotope & Radiation Corporation (CIRC), Alliance Medical, Advanced Accelerator Applications, JSC Isotope, Pharm-Sintez, Synektik SA, Polatom, RadioMedic sro, ÚJV Řež, Actinium Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Avid Radiopharmaceuticals, Fusion Pharmaceuticals, Peregrine Pharmaceuticals Inc., PETNET Solutions Inc., Positron Corporation, Triad Isotopes Inc., Telix Pharmaceuticals, Rosatom, Alliance Medical Group, Hologic Inc., Segami Corporation, Eczacýbaþý-Monrol Nuclear Products, NTP Radioisotopes.
Read the full radiopharmaceuticals market report here:
https://www.thebusinessresearchcompany.com/report/radiopharmaceutical-global-market-report
Which Region Is Forecast To Lead The Radiopharmaceuticals Market In Terms Of Market Size?
North America was the largest region in the global radiopharmaceuticals market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the radiopharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Radiopharmaceuticals Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3471&type=smp
Browse Through More Reports Similar to the Global Radiopharmaceuticals Market 2026, By The Business Research Company
Radiotherapy Devices Market Report 2026
https://www.thebusinessresearchcompany.com/report/radiotherapy-devices-global-market-report
Cancer Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report
Diagnostic Equipment Market Report 2026
https://www.thebusinessresearchcompany.com/report/diagnostic-equipment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model